

40年の歴史を持つ中南米



MERGERSCORP

40

この製薬会社はヨルダンのアンマンで約40年前に設立された。
70件以上の特許を保有し、技術革新におけるこの地域のベンチマークとなっている。

この技術革新の直接的な結果として、成熟した技術プラットフォームを独立した経営陣と経営資源を持つ子会社にスピンアウトさせることにより、従来のジェネリック医薬品業界の外に事業を多角化した。

垂直

- 1.中核となるブランドジェネリック医薬品事業
- 2.子会社を通じた天然物
- 3.子会社を通じたバイオテクノロジー診断薬。
- 4.子会社を通じた新しい賦形剤とドラッグデリバリーシステム。

製品紹介

製品は、循環器系、消化器系、中枢神経系、抗感染症系、内分泌系、筋骨格系、呼吸器系、産科・婦人科・泌尿器系、免疫系など、幅広い治療カテゴリーをカバーしている。

医薬品事業

消費者と医療専門家のニーズをカバーする200以上の医薬品を提供している。
これらの製品には錠剤、カプセル剤、坐剤、シロップ剤、懸濁剤などがあり、適正製造基準（GMP）に従って製造されている。同社の製品は高い“品質”を誇っており、大手製薬会社のひとつとしての競争優位性を持っている。

天然物

標準化された薬用植物エキスから植物・ハーブ医薬品の開発・製造を専門とする中東屈指の企業として知られ、世界20カ国以上で事業を展開し、50種類以上の天然・ハーブの革新的製品を提供している。

バイオテクノロジー

TARGET PRICE

\$45,000,000

GROSS REVENUE

\$37,000,000

EBITDA

\$6,279,944

BUSINESS TYPE

製薬

COUNTRY

ヨルダン

BUSINESS ID

L#20230509

同社は、独自のバイオテクノロジー・ヘルスケア製品の開発・製造を専門とする企業である。

The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction

The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.

By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.

This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.

The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.

All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.

MERGERSCORP

© 2026 MergersCorp M&A International. All rights reserved.

© 2026 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website <https://www.mergerscorp.com/disclaimer>. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.

MERGERSCORP

WWW.MERGERSCORP.COM